Category: medical

Not Enough Bullets

No Comments

Emergent BioSolutions, whose cavalier and incompetent business practices contaminated millions of vaccine doses, still saw fit to give huge bonuses to its top executives.

I’m not sure what the executives did, beyond taking millions of dollars in government subsidies:

Emergent BioSolutions, the biotech company whose Baltimore plant ruined millions of coronavirus vaccine doses, awarded hundreds of thousands of dollars in bonuses to its top executives last year, and the company’s board praised its founder and chairman for “leveraging his critical relationships with key customers, Congress, and other stakeholders,” according to documents released Wednesday by a House subcommittee.

………

Production at the plant was halted a month ago after workers accidentally contaminated a batch of vaccine, forcing Emergent to discard the equivalent of up to 15 million doses of Johnson & Johnson’s coronavirus vaccine.

Records from an Emergent board of directors compensation meeting offer a rare glimpse inside a politically connected federal contractor whose business is built largely around a single customer: the United States government.

The documents reflect earlier reporting by The New York Times, including a series of confidential audits that highlighted repeated violations of manufacturing standards at the Baltimore plant, including failure to properly disinfect the plant and protect against contamination of vaccine batches. Another report in June 2020, by a top manufacturing expert for the federal government, warned that Emergent lacked trained staff and adequate systems for quality control.

………

The board lauded executives for their “exemplary overall 2020 corporate performance including significantly outperforming revenue and earnings targets.”

Since 2018, Mr. El-Hibri and his wife, Nancy, have donated at least $150,000 to groups affiliated with the top Republican on the panel, Representative Steve Scalise of Louisiana, as well as Mr. Scalise’s campaigns. At least two other members of the subcommittee received donations during the 2020 election cycle from the company’s political action committee, which has given about $1.4 million over the past 10 years to members of both parties.

Mr. Kramer received a $1.2 million cash bonus, the records show; the board found that he had “significantly exceeded expectations.” Three of the company’s executive vice presidents received bonuses ranging from $445,000 to $462,000 each.

Sean Kirk, the executive responsible for overseeing development and manufacturing operations at all of Emergent’s manufacturing sites, received a special bonus of $100,000 last year, over and above his regular bonus of $320,611, in recognition of his “exceptional performance in 2020,” and for significantly expanding the company’s contract manufacturing capability to address Covid-19, the documents show. After the discovery that workers had accidentally contaminated a batch of Johnson & Johnson’s vaccine with the virus used to produced another vaccine at the same plant, the company said Mr. Kirk had taken personal leave from his job.

………

The $628 million contract, awarded by the Trump administration nearly a year ago, was mostly to reserve space at Emergent’s Baltimore plant for vaccine manufacturing. The contract was approved by a former Trump administration official, Dr. Robert Kadlec, who previously consulted for Emergent.

………

Dr. Kadlec has said that while he did not negotiate the contract, he did sign off on it. The documents also show that last August he recommended that Emergent be given a “priority rating” so that suppliers would give preference to its requests.

These guys should be sharing cells with the Capitol Insurrectionists.

So much of our economy these days consists of little more than stealing from the general public, whether with taxpayer money, (these guys) monetizing the public commons (Uber, Lyft, AirBnB, Lime, etc.), through indirect subsidies through IP provisions, (Media, Pharma, etc.) or the granting of special rights not held by ordinary people. (ISDS, TBTF, etc.)

If we stop these folks from stealing from us, there is no reason that we cannot have a better and more just society.

What About Turtles Farting?

No Comments

A series of studies have revealed that mammals can breath through the butt-holes.

Brought a bit of family lore, about turtles farting, to my mind:

When pressed for oxygen, some fish and sea cucumbers will use their lower intestines to get a little extra out of their environment. Now, a team of Japanese researchers say that mammals are also capable of respirating through their rectal cavity, at least in a lab setting.

The team’s research is published today in the journal Med and describes the capacity for mice, rats, and pigs to survive longer and have more strength in low-oxygen circumstances when given oxygen gas or an oxygen-rich liquid through their rectums, in a process similar to an enema. While fish like loaches and catfish use a similar method to gain additional oxygen in the natural world, this doesn’t appear to be an evolutionary adaptation for mammals. In other words, mammalian bodies can’t naturally do this, but with a little push from modern science, it becomes possible. Previous research has seen oxygen injected directly into mammalian bloodstreams, prolonging the lives of rabbits, but the rectal approach to the low-oxygen problem is novel.

The experiment, while disturbing, was designed to find new ways to save the lives of people whose lungs are failing.

It’s a valuable study, but all I can think about turtles farting.

 

My Heart Bleeds Borscht

No Comments

Elizabeth Holmes’ lawyers are desperately trying to hide her extravagant lifestyle from the jury, because they know how poorly this will fare with a jury.

Needless to say, the prosecution wants to include this information, both because it would make the jury hostile to her, and because it goes to motive.

I’m rooting for the prosecution:

Attorneys for Theranos Inc. founder Elizabeth Holmes sparred with federal prosecutors Thursday over whether details of the wealth, fame and perks she attained as chief executive would be relevant to jurors at her coming criminal fraud trial.

“What she wore, where she stayed, how she flew, what she ate—has nothing to do with this trial,” Kevin Downey, an attorney for Ms. Holmes, said in federal court in San Jose, Calif.

Ms. Holmes is facing a trial in late August on charges of wire fraud and conspiracy to commit wire fraud for alleged misrepresentations she made about Theranos’s blood-testing technology.

………

U.S. District Judge Edward Davila said Thursday he had concerns about whether prosecutors could talk about the popularity Ms. Holmes obtained as CEO along with perks such as the use of a private jet and stays in fancy hotels. Ms. Holmes was once worth $4.5 billion on paper. Mr. Downey said in court she received a salary of a “couple hundred thousand dollars a year,” which he said was probably less than many of her peers.

………

“The point here is the so-called success of Theranos was entirely the product of a fraud,” Assistant U.S. Attorney John Bostic said in court, arguing that details about her lifestyle are relevant because they can help show Ms. Holmes’ motive.

………

Attorneys for Ms. Holmes argued this week that jurors could unfairly view the violations found by the Centers for Medicare and Medicaid Services and Food & Drug Administration as proof that Ms. Holmes is guilty.

“The jury could convict based on violation of a regulation, that’s the danger,” Jean Ralph Fleurmont, a Williams & Connolly attorney representing Ms. Holmes, told the judge.

Ummm ……… That Theranos, and hence Holmes, was knowingly violating regulations goes to the heart of the fraud.

The fact that she repeatedly violated goes to intent, particularly when she threatened people who notified of her of problems.

Prosecutors said Ms. Holmes regularly cited Theranos’s compliance with federal standards to the press and in board meetings, making it relevant. The fact that they weren’t complying with industry standards is “a brick in the wall” that helps show the company’s tests “were not accurate or reliable,” assistant U.S. Attorney Robert Leach said.

I think that Elizabeth Holmes should be treated fairly and equally, by which I mean that she should be treated like a random minority accused of low level bunco.

I Think that His Consultant Gigs are at an End

No Comments

Maryland Attorney General Brian Frosh has announced that there will be a review of all the reports on in custody depths by former Chief Medical Examiner for the State of Maryland David Fowler following his clearly dishonest testimony at the Derek Chauvin.

Given that Fowler is currently being sued for covering up the eerily similar death of Angus Black under police restraint, it seems to me that Fowler’s days as a hired gun for bad cops are over.

As an aside, I am not at all surprised that he was born in what was then Rhodesia, (now Zimbabwe) and was did his medical school in Cape Town, South Africa, graduating from medical school in 1983,  working in South Africa until moving to the US in 1991.

It does appear that he has a rather long history of excusing law enforcement misconduct against people of color:

The Maryland’s Attorney General’s Office said Friday it believes there should be a review of “in custody” death reports produced by the state’s Office of the Chief Medical Examiner during the tenure of Dr. David Fowler, nine days after Fowler testified that an ex-Minneapolis police officer was not responsible for the death of George Floyd in police custody.

The announcement came less than 24 hours after the attorney general’s office received a letter from the former medical examiner of Washington, D.C., Roger A. Mitchell, signed by 431 doctors from around the country, saying Fowler’s testimony and conclusions were so far outside the bounds of accepted forensic practice that all his previous work could come into question.

“Dr. Fowler’s stated opinion that George Floyd’s death during active police restraint should be certified with an ‘undetermined’ manner is outside the standard practice and conventions for investigating and certification of in-custody deaths. This stated opinion raises significant concerns for his previous practice and management,” the letter said.

Attorney General Brian Frosh’s office said Friday afternoon that it agreed for the need to review Fowler’s work, and said it had been in contact with Gov. Larry Hogan’s staff.

“We agree that it is appropriate for independent experts to review reports issued by the Office of the Chief Medical Examiner (OCME) regarding deaths in custody,” Raquel Coombs, a spokeswoman for Frosh, said in an statement to The Baltimore Sun. “We are already in conversations with the Governor’s Office about the need for such a review, and have offered to coordinate it.”

Fowler testified that Floyd died of a sudden heart rhythm problem due to his heart disease while being restrained by police, contradicting several experts who said Floyd died due to a lack of oxygen. Former officer Derek Chauvin was convicted of murder and manslaughter for kneeling on Floyd’s neck.

………

Black’s 2018 death was captured on video, with Greensboro police holding the unarmed teenager down for more than six minutes. Fowler ruled that Black died because of a sudden cardiac event while struggling with police, and not because they pinned him in a prone position.

Testifying in the Floyd case, Fowler said that police, who held Floyd down in a prone position for more than nine minutes, did not cause Floyd’s death. His testimony was rebutted by a string of prosecution medical experts.

………

The office will review all cases from 2003-2020, which falls under Fowler’s tenure. He retired in 2019 after 17 years as chief medical examiner to go into private consulting practice. He was considered one of the foremost medical examiners in the country and served on national boards.

Included in that time period is the death of Tyrone West, who died after struggling with Baltimore Police following a traffic stop in 2013. Witnesses and the officers themselves said there was a violent struggle between the officers and West, but the state medical examiner’s office ruled that he died from natural causes exacerbated by the struggle and the summer heat. That ruling played a significant factor in the officers being cleared by the Baltimore State’s Attorney’s Office.

That the findings of the study are likely to support the lawsuit against him over the death of Angus Black is just the cherry on top of all of this.

Here is hoping that this guy’s professional reputation is destroyed.  It should have happened years ago.

It’s a Self Licking Ice Cream Cone

No Comments

The DEA has decided to keep classifying Marijuana as a Schedule 1 Drug, which means that they claim that it has no therapeutic value.

It also means that a large portion of the DEA’s budget, the part that is driven by its anti-pot activities, remains safe.

How convenient:

For the fourth consecutive time, the Drug Enforcement Administration has denied a petition to lessen federal restrictions on the use of marijuana.

While recreational marijuana use is legal in four states and D.C., and medical applications of the drug have been approved in many more, under federal law, it remains a Schedule 1 controlled substance, which means it’s considered to have “no currently accepted medical use” and a “high potential for abuse.”

The gap between permissive state laws and a restrictive federal policy has become increasingly untenable in the minds of many doctors, patients, researchers, business owners and legislators.

For instance, last fall, a Brookings Institution report slammed the federal government for “stifling medical research” in the area of marijuana policy. As a Schedule 1 drug, it’s much harder for researchers to work with marijuana than with many other controlled substances. The American Academy of Pediatrics has called on the government to move marijuana into Schedule 2 to facilitate more research into medical uses.

Perhaps this determination should be made by an organization whose budget is not contingent on it remaining illegal.

Your Daily Schadenfreude

No Comments

Elizabeth Holmes, CEO of Theranos has just had her personal wealth recomputed by Fortune. Yesterday,   it was $4,500,000,000.00 today it is $0.00:

Last year, Elizabeth Holmes topped the FORBES list of America’s Richest Self-Made Women with a net worth of $4.5 billion. Today, FORBES is lowering our estimate of her net worth to nothing. Theranos had no comment.

Our estimate of Holmes’ wealth is based entirely on her 50% stake in Theranos, the blood-testing company she founded in 2003 with plans of revolutionizing the diagnostic test market. Theranos shares are not traded on any stock market; private investors purchased stakes in 2014 at a price that implied a $9 billion valuation for the company.

Since then, Theranos has been hit with allegations that its tests are inaccurate and is being investigated by an alphabet soup of federal agencies. That, plus new information indicating Theranos’ annual revenues are less than $100 million, has led FORBES to come up with a new, lower estimate of Theranos’ value.

FORBES spoke to a dozen venture capitalists, analysts and industry experts and concluded that a more realistic value for Theranos is $800 million, rather than $9 billion. That gives the company credit for its intellectual property and the $724 million that it has raised, according to VC Experts, a venture capital research firm. It also represents a generous multiple of the company’s sales, which FORBES learned about from a person familiar with Theranos’ finances.

At such a low valuation, Holmes’ stake is essentially worth nothing. Theranos investors own preferred shares, which means they get paid back before Holmes, who owns common stock. According to VC Experts, investors in Theranos own a particular kind of preferred equity, called participating preferred shares, which take precedence to common stock in the event of a liquidation. FORBES is not aware of any plans to liquidate. If that were to happen, participating preferred investors would get their money back and more before Holmes gets a cent.

We now know the difference between a typical Silicon Valley company and one that actually has to produce a real physical product:  The emperor’s new clothes are revealed far sooner for the companies who make actuall “stuff”.

It appears that the medical testing industry does not lend itself to the “long con.”

Well, This Explains a Lot

No Comments

It turns out that over the past 70 years, many medical conditions that were considered normal are not considered pathologies that require aggressive treatment.

There is a lot of money in this, which raises the obvious question, “cui bono?”

As many as 16 million Americans are prone to screaming and pounding on the dashboard when someone cuts them off in traffic. Another 7 million are fully capable of devouring a whole box of cookies in front of the TV.

There are 14 million men with low testosterone, 9 million women with low sexual desire — and tens of millions of people with bladders that are too active and blood sugar that’s a little too high.

The common thread: All have non-life-threatening conditions that for most of the 20th century were not considered a part of mainstream medicine. Some did not exist at all as formal disorders.

Each of the conditions, from intermittent explosive disorder to overactive bladder disorder, is the product of a new or expanded definition. These definitions come from medical societies or researchers who get money from drug companies.

Not to worry though, I’m sure that the invisible hand of the market, and the “skin in the game” required by Obamacare, will fix all this.

She’s Fundraising with Theranos? Seriously?!?!?

2 Comments

For a while, I have been talking about the smoke and mirrors show that is the lab test company Theranos.

The short version is that they have a multibillion dollar valuation for a technology that allows one to make blood tests from a drop of blood from a finger tip.

Unfortunately, they have not been able to make the technology work, and so they have been doing conventional tests to generate some revenue.

But they are f%$#ing this up too, having been cited by the FDA.

And now the Clinton campaign is having this den of fraud hold a fund raiser for them.

I guess that Enron was busy:

Theranos is a unicorn that may soon be sent to the glue factory. The biotech start-up was once the toast of Silicon Valley. Its signature technology — a blood-testing machine so sensitive it requires a mere pinprick of blood to make accurate diagnoses — attracted a $9 billion valuation. ……… And then, last October, The Wall Street Journal revealed that the company’s breakthrough technology doesn’t actually work.

In recent days, the Centers for Medicare and Medicaid Services found that the company’s lab in Newark, California, was in violation of five federal regulations, thereby posing “immediate jeopardy to patient health and safety.” Last week, the release of that investigation’s full report revealed that “quality control issues” may have compromised the blood-test results of 81 patients.

……… But for god knows what reason, it hasn’t cost the company the chance to host a fund-raiser for the Democratic front-runner. Next week, Chelsea Clinton will join Holmes at Theranos’s Palo Alto headquarters to help raise money for her mother’s campaign. According to an email obtained by Re/code, the event will be held next Monday night and will cost most attendees $2,700 a head.

One of Clinton’s primary liabilities in her race against Bernie Sanders is the perception that she is overly friendly with corrupt corporate interests. So it’s pretty bizarre that she has decided to have a (reportedly) corrupt corporation host her next big fund-raiser. And it’s only one of several unforced errors the campaign has made since last Friday. 

Someone in the Clinton sure picked the wrong week to stop sniffing glue.

On the bright side for the Campaign, at least this time Hillary was not caught on camera doing it, so she can blame some lowly staffer.

This really is a complete cock up.

It Appears that Unicorns* Don’t Believe in Due Diligence

No Comments

We have another shoe dropping at Theranos Lab:

U.S. health inspectors have found serious deficiencies at Theranos Inc.’s laboratory in Northern California, according to people familiar with the matter.

 The problems were found during an inspection by the Centers for Medicare and Medicaid Services, the chief federal regulator of clinical labs, at the blood-testing company’s facility in Newark, Calif. Failing to fix the problems could put the Theranos lab at risk of suspension from the Medicare program.

 The inspection results are expected to be publicly released soon, these people said. A spokesman for the agency said it “can’t confirm any survey conclusions or results at this time.”

 ………

 Theranos already has stopped collecting tiny samples of blood from patients’ fingers for all but one of its tests while it waits for the Food and Drug Administration to review the company’s applications for wider use of the proprietary vials called “nanotainers.” In October, the FDA said it had determined that the nanotainers were an “uncleared medical device.”

 Since then, Theranos has been performing just one test—to detect herpes—using its proprietary Edison device, people familiar with the matter said. That test was approved by the FDA.

 Theranos is using traditional machines for the rest of the more than 200 tests it offers to consumers, the people said.

Theranos has been a hawking a proprietary technology which allows for a wide range of blood tests to be conducted by a simple finger prick.

They have a valuation of over $1 billion, their technology does not work reliably. their conventional lab tests have been cited by the FDA, and most of their business they have to outsource at a loss.

I understand that this Might Be a promising technology, but how does this become a multibillion dollar valuation?

How is there difference between this and much of the rest of the froth in Silicon Valley?

There are no venture capitalists.  There are just con men looking for the next idiot.

*In the world of business, a unicorn is a company, usually a start-up that does not have an established performance record, with a stock market valuation or estimated valuation of more than $1 billion.

Can We Give Florida Back to Spain?

No Comments
In response to donations from sub-par hospitals to the state Republican Party, Florida has abandoned surgical standards for hospitals:

Children’s heart doctors in Florida are reeling from a recent decision by the state to drop surgical standards for pediatric open heart surgery, CNN reports. To add insult to injury, doctors and medical experts suspect that the decision was purely political.

The decision follows a 2014 medical review and a June 2015 report by CNN, which found that one particular medical facility, St. Mary’s Medical Center and Palm Beach Children’s Hospital, had an abysmal track record for pediatric open-heart surgery—a death rate more than three times the national average. And the two reports found that the facility was failing to meet the now-repealed standards, which include proficiency in performing the surgeries themselves.

The St. Mary’s facility is run by Tenet Healthcare, which coincidentally donated $200,000 to the state’s republicans between 2013 and 2014, including $100,000 to Republican Governor Rick Scott’s political action committee. Those donations were the highest of any Tenet gave to political groups in other states.

A month after CNN’s report, the state announced that it would repeal the standards for children’s heart surgery. Florida’s health department explained the move by saying that the standards were never properly approved by the legislature, but it failed to explain to reporters why legislative approval was not sought upon realizing the lapse.

It appears that Florida is in a competition with Texas for most repulsively corrupt politics in the United States.

How Did This Company Get Any Backers?

No Comments

Looks Like VC Pump and Dump Bullsh%$to Me

In the continuing revelations regarding the Silicon Valley-eaque medical startup, I have come to the conclusion that it’s investors, and its market cap, are more a product of its founder is an earnest attractive blond who dropped out of Stanford.

First it was repeated reports that their technology failed to work even in highly scripted dog and pony shows for potential investors, now we discover that the company was doing of this while using regulatory loopholes to avoid FDA oversight:

This suggests one of two possibilities: either Theranos’ customers received test results generated by equipment that no federal official checked for accuracy, or Theranos wasn’t using the proprietary technology behind its $9 billion valuation to return results to patients. A recent report from The Wall Street Journal pointed toward an extreme version of option number one: that Theranos actively hid its proprietary technology from lab inspectors, which would explain why the inventions were never checked. And Theranos has publicly proclaimed it used its technology on patients, which means either that the company’s lying or patients received tests that had not been validated by any federal authorities.

“CMS did not inspect the Theranos proprietary technology.”Theranos first came under scrutiny after a report in the Journal in October, which said that Theranos’ inventions were only used on a small number of tests sold to patients. On Sunday, the paper reported that during an inspection by Centers for Medicare and Medicaid Services auditors, employees who worked in the “Normandy” section of the Theranos lab were told not to enter or exit the lab; the inspectors toured the section of the lab that housed traditional lab instruments Theranos bought from other companies but never saw the Edison machines — Theranos’ highly publicized blood analyzers. This account fits with lab inspection documents that The Verge obtained from CMS, which do not mention Theranos’ proprietary technology at all. There’s a reason for that: “CMS did not inspect the Theranos proprietary technology,” a spokesperson for CMS told The Verge in an email. Consequently, at no point between Theranos opening its first wellness center in 2013 and a surprise inspection by the FDA in August did any federal official examine the company’s proprietary technology — either its Edison machine, which reads samples, or its “Nanotainer” device, which stores blood from pinprick testing.

The lack of inspection was possible in part because Theranos registered its technology in categories that have minimal oversight. Theranos sold its tests under a designation that even the US Food and Drug Administration calls a regulatory loophole: the “lab-developed test.” Under this designation, no pre-market FDA approval is required for the company’s blood tests — as it typically is for most drugs and devices. The category was meant for research hospitals, which sometimes adapt commercial tests to suit patients’ needs, and Theranos is one of several companies using the loophole to sell its tests to the public. Instead of the FDA, regulation of Theranos’ labs fell to the Centers for Medicare and Medicaid Services.

Theranos also registered its blood containers as FDA Class I medical devices in 2013, according to the FDA. That category of medical device doesn’t require an FDA inspection. No FDA inspectors entered a Theranos facility until August of this year, during a round of surprise inspections. In the FDA’s inspection report, it referred to Theranos’ Nanotainer as an “uncleared medical device” and altered its registration to a Class II medical device, which requires greater oversight.

CMS declined to provide us with additional information about Theranos. The FDA provided some information about Theranos’ regulatory status — including the fact that Theranos registered its containers as Class I in 2013 — but declined to reveal anything further about the company.

I’m beginning to think that the whole startup culture is a code word for some sort of charity for overpriviliged white boys.

The Past 48 Hours in Criminal Justice has Been a bit of a Roller Coaster

No Comments
Yesterday, I looked out the window at work, and saw 2 helicopters hovering about 5000 feet up in the general direction of Lexington Market.

On closer examination, I noticed that they were both news choppers, as I saw the cameras, and I figured that something had happened in the first Freddie Gray trial.

It turned out that we had a hung jury and a mistrial:

A judge declared a mistrial Wednesday in the case of Baltimore Police Officer William G. Porter after jurors said they had failed to reach an agreement on any of the charges against him in the death of Freddie Gray.

 The decision, which came a day after jurors told Baltimore Circuit Judge Barry Williams they were deadlocked, frustrated activists who had watched the first trial in Gray’s death closely. Outside the downtown courtroom, city officials and community leaders pleaded for calm, and authorities reported two arrests, but no violence or serious disruptions.

 Porter, 26, the first of six police officers to be tried in Gray’s death, remains charged with involuntary manslaughter, second-degree assault, reckless endangerment and misconduct in office. Gray, 25, died in April after suffering a severe spinal cord injury in the back of a police van.

 Jurors deliberated for three days before Williams declared the mistrial. The decision now throws the other trials into flux.

 Prosecutors chose to try Porter first, planning to use him as a witness at the trial of Officer Caesar Goodson. Goodson, who is charged with second-degree murder, was slated for trial in the first week of January.

I can’t imagine that the States Attorney Marilyn Mosby is not going to announce her intention to retry him soon.

Even ignoring the political overtones, if she gives up, she has no leverage at all about getting him to testify against his superiors.

Even so, it’s kind of depressing.

On the other hand, the announcement that “Pharma Bro” Martin Shkreli had been arrested for securities fraud:

It has been a busy week for Martin Shkreli, the flamboyant businessman at the center of the drug industry’s price-gouging scandals.

He said he would sharply increase the cost of a drug used to treat a potentially deadly parasitic infection. He called himself “the world’s most eligible bachelor” on Twitter and railed against critics in a live-streaming YouTube video. After reportedly paying $2 million for a rare Wu-Tang Clan album, he goaded a member of the hip-hop group to “show me some respect.”

Then, at 6 a.m. Thursday, F.B.I. agents arrested Mr. Shkreli, 32, at his Murray Hill apartment. He was arraigned in Federal District Court in Brooklyn on securities fraud and wire fraud charges.

In a statement, a spokesman for Mr. Shkreli said he was confident that he would be cleared of all charges.

Mr. Shkreli has emerged as a symbol of pharmaceutical greed for acquiring a decades-old drug used to treat an infection that can be devastating for babies and people with AIDS and, overnight, raising the price to $750 a pill from $13.50. His only mistake, he later conceded, was not raising the price more.

The picture of him being hauled off in handcuffs (above) just made my day. (Does this make me a bad person?)

The comment of the day on this comes from the inimitable Charlie Pierce, “I suppose he could argue for a change of venue, but I think it impractical to delay the trial until we make it to Mars.”

Honestly, I think that it would be impossible to find a jury that wouldn’t want to give him the death penalty for jaywalking.

This Smells Like a Coverup,

No Comments

U.S. Military Suspends Members Over Kunduz Hospital Strike – The New York Times

The top American commander in Afghanistan, Gen. John F. Campbell, said Wednesday that several service members had been suspended from duty after an internal military investigation of the American airstrike on a Doctors Without Borders hospital in Kunduz last month.

 Calling the airstrike a “tragic mistake,” General Campbell read a statement announcing the findings of the investigation, which he said concluded that “avoidable human error” was to blame, compounded by technical, mechanical and procedural failures. He said another contributing factor was that the Special Forces members in Kunduz had been fighting continuously for days and were fatigued.

The special forces were “Fatigued”.

Sounds like, “The dog ate my homework.”

General Campbell and his staff did not say how many people were being disciplined, or how. But a senior United States military official, speaking on the condition of anonymity, said that one of those punished was the Army Special Forces commander on the ground in Kunduz during the fighting. The official would not identify the commander by name, but said the officer, a captain, was relieved of his command in Afghanistan on Wednesday morning.

Translation: he is the the chosen patsie, because he is only a captain.

This what happens in these cases:  They lay everything at as low a level as is possible, and/or blame reservists or national guardsman.

Kunduz, a provincial capital in northern Afghanistan, had been seized by the Taliban in the days before the airstrike. General Campbell said the gunship’s crew believed it was firing on a different building identified as a Taliban base in the city. He said that the aircraft’s targeting systems failed to deliver accurate information and that email and other electronic systems aboard the aircraft, including a video feed that would normally have sent pictures to higher-level commanders in real time, also failed during the operation.

Seriously?

The general confirmed that Médecins Sans Frontières, the French name of Doctors Without Borders, had succeeded in reaching the Special Forces commander to inform him of the attack about 12 minutes into the airstrike, at 2:20 a.m. But he said the strike was not called off until 2:37 a.m. — after the aircrew had already stopped firing. But that timeline does not agree with accounts by the aid group and other witnesses, who said the strike went on for more than an hour.

The aid group, which has called for an independent, nonmilitary international inquiry into the airstrike, was sharply critical of General Campbell’s remarks. “The U.S. version of events presented today leaves M.S.F. with more questions than answers,” said Christopher Stokes, the organization’s general director. “The frightening catalog of errors outlined today illustrates gross negligence on the part of U.S. forces and violations of the rules of war.”

Gee, you think?

This stinks to the high heavens.

(on edit)

And the fact that they dumped this the day before thanksgiving is also highly suspect.

F%$# Me, I Agree with Bill O’Reilly

No Comments

Over the weekend, George Will and Bill O’Reilley got into it over whether or not Reagan was show signs of Alzheimers in his first term, and whether his shooting by John Hinkley might have accelerated the progress of the condition.

Bill O’Reilly is right about this, and so does Charlie Pierce. (I just threw up in my mouth)

It’s a medical fact that trauma can accelerate the progress of dementia, and there are numerous accounts of of the Gipper checking out in his first term, his first debate performance against Walter Mondale being one.

​One of our top commenters suggested that my account Monday morning of the dust-up between George Effing Will and Bill O’Reilly was incomplete because I failed to mention the precise casus belli. The Top Commenter is absolutely correct, and my omission is all the more odd because it involves a personal tin drum that I’ve been pounding since I wrote my Alzheimer’s book in 2000. It also involves one of the most serious of all history’s Unspoken Truths. What set Will’s chilly blood aflame apparently was the fact that, in his book, Killing Reagan, O’Reilly pretty baldly states that Ronald Reagan was a symptomatic Alzheimer’s patient for most of his presidency, and that having been shot was trauma enough to start what AD researchers call a “cascade” of symptoms that accelerated the progress of his disease.

(As it happens, O’Reilly’s speculation is on solid scientific footing. Alzheimer’s researchers and caregivers have known for years that physical trauma can worsen the effects of the disease. Certainly, the recent  research into the connection between head trauma and dementia backs this up, and I remember a fascinating Japanese study at an Alzheimer’s research conference that I attended in Osaka that studied the effect of a massive earthquake in that country on Alzheimer’s patients in the affected regions. In almost all cases, the disease accelerated.)

I am not willing to go as far as O’Reilly apparently does, but I have believed—and written—for years that Reagan was a symptomatic AD patient at least throughout his entire second term. My initial concern in this regard arose in 1984, during Reagan’s first debate with Walter Mondale, when he plainly did not know where he was or what he was supposed to be doing. At the time, my father was beginning a slow slide into Alzheimer’s himself. I knew what I was looking at on TV—and so, I learned later, did Dr. Dennis Selkoe, a prominent AD researcher in Boston. Since then, accounts of Reagan’s curiously vacant episodes have popped up all over various historical accounts, and personal memoirs, of the Reagan presidency. In the latter case, everybody from Ollie North to Lawrence Walsh mentions at least one moment in which the person who was Ronald Reagan disappeared right before their eyes. In an interview in 1999 for this magazine, John McCain told me of his experience at a White House dinner, when Reagan lapsed into some middle space of his own.

Seriously, while I have no problem with disagreeing with George will, the fact that this involves me agreeing with Bill O’Reilly makes me feel a bit sick.

A ‘Huge Milestone’: Until the Zombies Apocalypse, Anyway

No Comments

It appears that the folks in biotech are lauding a treatment of cancer using viruses:

A new cancer treatment strategy is on the horizon that experts say could be a game-changer and spare patients the extreme side effects of existing options such as chemotherapy.

Chemotherapy and other current cancer treatments are brutal, scorched-earth affairs that work because cancer cells are slightly – but not much – more susceptible to the havoc they wreak than the rest of the body. Their side effects are legion, and in many cases horrifying – from hair loss and internal bleeding to chronic nausea and even death.

Imlygic, which bursts melanoma cells open and triggers immune response, can shrink localised tumours but is not proven to extend life, says FDA

But last week the Food and Drug Administration (FDA) for the first time approved a single treatment that can intelligently target cancer cells while leaving healthy ones alone, and simultaneously stimulate the immune system to fight the cancer itself.

The treatment, which is called T-VEC (for talimogene laherparepvec) but will be sold under the brand name Imlygic, uses a modified virus to hunt cancer cells in what experts said was an important and significant step in the battle against the deadly disease.

Hmmmm…. A revolutionary virus based cancer treatment..

Recall a zombie flick that started with that.

I really hope that the FDA has done proper due diligence.

Of Course, the Germans Have a Word for It

No Comments

Fachidiot (Google Translate)

It means someone who has achieved a measure of accomplishment in their own field, but area complete blithering idiot outside of this narrow area of expertise.

Who epitomizes this word?

Who could it be?

Oh, I dunno, maybe a world renowned neurosurgeon who makes Donald Trump look smart and sane Presidential Candidate by comparison?

It’s not surprising to find a Surgeon in this position.

One of the open secrets of the medical profession is that doctors work with their minds, and surgeons work with their hands.

Former Senate leader Bill Frist is another classic example of this phenomenon.

Surgery is not a “big picture” line of work. You open you fix, you close.

Diagnosis, by contrast is a process by which you take a constellation of sometimes conflicting information, and create a synthesis.

One of these things involves a big picture and critical thinking.

The other is surgery.

Entitled Idiots Who Should Not Have Your Money

No Comments

Nobody likes to be questioned.

But lately, some of Silicon Valley’s big tech investors seem to be particularly upset that journalists are questioning some of the valley’s hottest startups.

There’s a fundamental difference in point of view here. The funders see first-hand how hard it is to build something and sympathize with the struggle. The journalists are supposed to be as objective and careful as possible and report what they find — even if some people don’t like it.

The latest example is Theranos, whose science was called into question by The Wall Street Journal on Thursday. Theranos founder Elizabeth Holmes was quick to defend her company, as you’d expect from a CEO.

But some VCs also seemed genuinely upset. Not at the substance of the allegations, but for not giving founders the benefit of the doubt when it comes to building something.

………

Startup founders have a really hard job. They are trying to do something new and drive society forward. The tech press doesn’t know all the facts so you should give them a break.

The first sentence is indisputably true — it’s hard (and lonesome) to found a tech startup.

………

The second sentence is where things get sticky.

A lot of tech founders are trying to do something new and drive society forward. But some of them are not.

………

The third sentence is where they completely miss the point.

Journalists don’t set out to write takedowns of companies. But when a journalist begins investigating a company and finds something is amiss, and the story is well vetted and fairly reported, the venture community should welcome that reporting.

I’m beginning to think that of all the problems facing the business culture of the United States , it is the Ayn Rand inspired corrosive narcissism which is worst of all.

If you look at Theranos, for example, the facts are fairly clear.

The company has misrepresented the scope of its technology, and there have been repeated reports that the at least some of the tests are significantly less accurate.

This technology may, or may not, be successful at a later date, but it is clear that its valuation, one which makes its CEO a billionaire is Silicon Valley “Unicorn” bullsh%$.